Immune checkpoint inhibitors for unresectable hepatocellular carcinoma

MA Abd El Aziz, A Facciorusso, T Nayfeh, S Saadi… - Vaccines, 2020 - mdpi.com
Despite the advances in screening protocols and treatment options, hepatocellular
carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver …

Poor responses and adverse outcomes of myasthenia gravis after thymectomy: predicting factors and immunological implications

K Chen, Y Li, H Yang - Journal of Autoimmunity, 2022 - Elsevier
Myasthenia gravis (MG) has been recognized as a series of heterogeneous but treatable
autoimmune conditions. As one of the indispensable therapies, thymectomy can achieve …

Clinical profile and impact of comorbidities in patients with very‐late‐onset myasthenia gravis

J Vijayan, D Menon, C Barnett, H Katzberg… - Muscle & …, 2021 - Wiley Online Library
Abstract Introduction/Aims The purpose of this study was to evaluate the clinical profile of
myasthenia gravis (MG) in older patients and determine the impact of medical comorbidities …

Benefit and danger from immunotherapy in myasthenia gravis

C Rodolico, G Nicocia, V Damato, G Antonini… - Neurological …, 2021 - Springer
In the last years, significant advances have improved the knowledge of myasthenia gravis
(MG) immunopathogenesis and have enabled to realize new molecules with a selective …

Antibiotics with antibiofilm activity–Rifampicin and beyond

L Ferreira, E Pos, DR Nogueira, FP Ferreira… - Frontiers in …, 2024 - frontiersin.org
The management of prosthetic joint infections is a complex and multilayered process that is
additionally complicated by the formation of bacterial biofilm. Foreign material provides the …

Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy

G Crescioli, M Finocchietti, O Paoletti, P Brunori… - Frontiers in …, 2023 - frontiersin.org
Introduction To evaluate the use of pyridostigmine in presence of contraindications, and the
use of concomitant potentially contraindicated drugs in a cohort of patients affected by …

Neuromuscular junction disorders beyond myasthenia gravis

SJ Oh - Current Opinion in Neurology, 2021 - journals.lww.com
Neuromuscular junction disorders beyond myasthenia gravis : Current Opinion in Neurology
Neuromuscular junction disorders beyond myasthenia gravis : Current Opinion in Neurology …

Childhood myasthenia gravis in Japan: Pathophysiology and treatment options

M Hayashi - Clinical and Experimental Neuroimmunology, 2023 - Wiley Online Library
Myasthenia gravis (MG) is a disease that causes muscle weakness and fatigue due to an
abnormality in the neuromuscular junction, which prevents the transmission of information …

Optimization of Application-Driven Development of In Vitro Neuromuscular Junction Models

JB Strickland, K Davis-Anderson… - … Engineering Part B …, 2022 - liebertpub.com
Neuromuscular junctions (NMJs) are specialized synapses responsible for signal
transduction between motor neurons (MNs) and skeletal muscle tissue. Malfunction at this …

The management of hypercholesterolemia in patients with neuromuscular disorder

WJ Loh, GF Watts - Current Atherosclerosis Reports, 2023 - Springer
Abstract Purpose of Review We describe and discuss the safety of statins and non-statin
drugs in neuromuscular disorders (NMDs). We also propose a pragmatic model of care for …